Azithromycin: The Holy Grail to Prevent Exacerbations in Chronic Respiratory Disease?-Reference-Cited by-同舟云学术

Azithromycin: The Holy Grail to Prevent Exacerbations in Chronic Respiratory Disease?

Published:2019-08 Issue:3 Volume:200 Page:269-270
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Welte Tobias¹

Affiliation:

1. Department of Respiratory Medicine and Infectious DiseasesMedizinische Hochschule Hannover, Member of the German Center of Lung ResearchHannover, Germany

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.201903-0706ED

Reference15 articles.

1. Improvement of Survival in Patients with Diffuse Panbronchiolitis Treated with Low-dose Erythromycin

2. Long-Term Azithromycin for Bronchiolitis Obliterans Syndrome After Lung Transplantation

3. Azithromycin in Patients With Cystic Fibrosis Chronically Infected With Pseudomonas aeruginosa

4. Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Longitudinal lung function trajectories in response to azithromycin therapy for chronic lung disease in children with HIV infection: a secondary analysis of the BREATHE trial;BMC Pulmonary Medicine;2024-07-12

2. In Vivo Immune-Modulatory Activity of Lefamulin in an Influenza Virus A (H1N1) Infection Model in Mice;International Journal of Molecular Sciences;2024-05-15

3. Azithromycin therapy in infants hospitalized for respiratory syncytial virus bronchiolitis;Annals of Allergy, Asthma & Immunology;2024-05

4. Azithromycin Exposure Induces Transient Microbial Composition Shifts and Decreases the Airway Microbiota Resilience from Outdoor PM _2.5 Stress in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled Trial;Microbiology Spectrum;2023-06-15

5. Mass drug administration of antibacterials: weighing the evidence regarding benefits and risks;Infectious Diseases of Poverty;2022-06-30